Crohn's disease [CD] is a chronic relapsing systemic disease affecting the gastrointestinal tract. An altered immune response to commensal intestinal bacteria takes place in genetically predisposed individuals, resulting in chronic inflammation in the gut. Several alterations in the innate immunity mechanisms have been described in recent years. Thus, the study of the immunological aspects of CD, specifically the role of lymphocytes, is a key element for understanding the pathogenesis of the disease. Gammadelta T cells [γδ T cells] constitute only a small proportion of the lymphocytes that circulate in the blood and peripheral organs and they are present mainly in the epithelia, where they can constitute up to 40% of intraepithelial lymphocytes [IEL] in the intestinal mucosa. Due to their lack of major histocompatibility complex [MHC] restriction and their unique plasticity and immuneregulating properties, they are considered key cells in the first line of defence against infections and in wound healing in the gut. Although there is growing experimental and clinical evidence of their implication in inflammatory bowel disease [IBD], including CD, their clinical relevance is still unclear. In this review, we address the possible involvement of γδ T cells in the pathogenesis of CD, reviewing their role against infections and in inflammation and the current evidence suggesting their implication in CD, offering a novel potential target for immunotherapy in IBD.
Introduction
Crohn's disease [CD] is a chronic recurrent inflammatory process that can affect any part of the gastrointestinal tract and may present also with extraintestinal manifestations, leading to a significantly compromised quality of life for patients and high associated health care costs. 1, 2 Despite the sharp increase in its incidence in recent decades 3 and the important advances made in understanding the mechanisms underlying CD, the aetiopathogenesis of the disease remains largely unknown. CD is currently considered a polygenic immune disorder due to multiple causes, in which the following are involved: 1] individual genetic factors; 2] environmental factors; 3] intestinal flora
[microbiome]; and 4] immune response. A combination of these factors triggers an inappropriate immune response against the commensal flora in genetically predisposed subjects. 4, 5 Some evidence points to the fact that CD could be an immune deficiency condition. 6, 7 Several alterations in the innate immunity mechanisms have been reported in recent years, leading to the presence of micro-infections that are not efficiently resolved by the immune system, perpetuating an exaggerated inflammatory immune response. [6] [7] [8] [9] [10] Hence the study of the immunological aspects of CD and, more specifically, the role of lymphocytes, is a key element in understanding the pathogenesis of the disease.
There is a growing body of evidence from both basic and clinical research that suggests that CD would be essentially a primary immunodeficiency rather than an autoimmune process in the proper sense of the term. That is to say, patients with CD present a genetically determined flaw in their immune system [basically in their innate or nonspecific immunity], with an identifiable phenotype which, as a result, can suffer unresolved recurrent infections and chronic 'autoinflammation' with the secondary appearance of autoimmune phenomena or neoplasia. This aspect has been analysed in recent reviews. 6, 7 In fact, genetic alterations have been reported in mechanisms directly involved in the recognition [like the nucleotide-binding oligomerisation domain-containing protein 2, NOD2] 8 and clearance of intracellular organisms and certain bacteria [like the autophagyrelated protein 16L, ATG16L1]. 9 Moreover, the fact that the typical lesions occur in the areas of greater bacterial density [ileum and rectum], and the improvement of inflammation in areas where faecal transit has been deviated, make recurrent response to microbes a plausible mechanism for maintaining inflammation. 4, 5 Proof of the presence of adherent-invasive Escherichia coli [AIEC] in the granulomas of patients would support this possibility. 10 In addition, there are other disorders in innate immune mechanisms that contribute to the appearance of recurrent inflammation in CD, such as: 1] alterations in the mucosal layer; 2] alterations in the intestinal permeability; 3] dysfunction of Paneth cells [and the production of defensins] and of macrophages; or 4] alterations in the stress mechanisms of the endoplasmic reticulum [excellent reviews in refs 4 and 5 ]. Gammadelta T cells [γδ T cells] constitute only a small proportion of the lymphocytes that circulate in the blood and peripheral organs and they are present mainly in the epithelia, where they can account for up to 40% of intraepithelial lymphocytes [IEL] in the colonic mucosa. 11, 12 Due to their lack of major histocompatiblitity complex [MHC] restriction and their singular plasticity and immunoregulatory properties, they are considered key cells in the first line of defence against infections and in wound healing. [13] [14] [15] [16] These unique features, their known participation in the pathogenesis of autoinflammatory conditions, 17 and the results of animal [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] and human studies, point to an important role of γδ T cells in the recurrent inflammation and ulcerations seen in CD.
However, their clinical relevance in IBD, including CD, is still unclear. Our aim in this review is to examine the existing evidence on the role played by alterations in γδ T cells as a possible new factor in CD pathogenesis, as these cells are essential to innate immunity in the first line of defence against infection in the mucosa, and play a key role in immunoregulation and tissue repair.
Gammadelta T Cells

General aspects of γδ T cells
T cells can be divided into two large sub-populations according to the antigen receptor that they express on the surface membrane [T-cell receptor or TCR]: the alphabeta T cells [αβ T cells] and the γδ T cells. 42 TCR is a heterodimer that can be composed of two chains: α and β or γ and δ. Its expression is exclusive, that is a T cell can only express one of these two phenotypic variants [αβ or γδ] . 43 This heterodimer is associated with the CD3 complex in the cell membrane. 42 Since the discovery of γδ T cells in 1984 by Saito et al., 44 there has been a growing interest in revealing the biological functions of these lymphocytes. Today, they are considered a key element in the first line of defence against invasive pathogens in the epithelia, as well as in the homeostasis of the immune response. 16, 43 αβ T cells are the largest population of T lymphocytes in peripheral blood [PB] , where they account for up to 95% of the circulating T cells. Contrary to γδ T cells, they respond mainly to antigens that are processed and presented by antigen-presenting cells [APC] in molecules of the major histocompatibility complex [MHC] . 42, 58 Their response is therefore restricted and delayed. 43 However, not all αβ T cells respond to processed antigens in an MHC-restricted fashion; there is evidence that other antigen-presenting molecules, like CD1, display also lipids and small molecules to αβ T cells. 45 
Subtypes and phenotypic classification of γδ T cells
γδ T cells are the first T cells to develop in vertebrates and the first to appear in the foetal thymus, and they make up the greater subpopulation of T cells during the first year of life, which is suggestive of their key role in neonatal protection while the IgA protective system is still not fully developed. 43 In fact, restricted Vδ2+ cells with pre-programmed effector function are already the predominant γδ T cell subset circulating in human foetal blood before exposure to pathogens. 46 γδ T cells can be classified into two main populations, according to TCR expression: Vδ1+ and Vδ2+ [also known as Vγ9Vδ2 because this is its major phenotype]. 43 Vδ1+ are predominant in epithelia where they usually express the marker CD8+, present characteristics of motility and migration to the mucous membranes [adherence, emission of long filopodia, etc.], and play a crucial role in epithelial regeneration. [13] [14] [15] Vδ2+ [Vγ9Vδ2] is the predominant subtype in PB and possesses a greater natural killer [NK] and antibody-mediated cytotoxic capacity. 47, 63, 65 These features make this cell subtype highly interesting for cancer immunotherapy. 48, 49 Recently a third subtype, Vδ3+, has been found in the intestinal mucosa. 50 They constitute only about 0.2% of T cells in the PB, but they can be more frequent in the liver, in some chronic viral infections and in patients with leukaemia, and are glycolipid-reactive. 51 Most of the peripheral γδ T cells are double negative for CD4 and CD8 [CD4-CD8-]. 11 However, intestinal γδ IEL are frequently CD8+ [50% of γδ IEL]. 12 Recent data show that certain γδ T cell subsets in the human colon are specifically regulated locally by the gut epithelium. 52 
Differences between αβ T cells and γδ T cells
There are three fundamental characteristics that differentiate γδ T cells from αβ T cells [ Figure 1 ], as follows: 1) γδ T cells are mainly located in the mucosa, accounting for up to 40% of the IELs and acting as the first line of mucosal immune defence. Contrary to αβ T cells, they are scarce in peripheral blood [PB] and the secondary lymphoid organs. 11, 12, 43 During infections, however, the proportion of γδ T cells in PB may increase considerably, to the extent that they can make up to 30% of the circulating T cells. 53 2) γδ T cells recognise proteins directly without previous antigenic processing by antigen-presenting cells [APC] or their presentation by MHC molecules. 54 Vδ2+ are also able to recognise a wide range of non-peptide ligands 55, 56 ; whereas Vδ1+ T cells can recognise MICA/B molecules [MHC-class I related molecules] inducible by cell stress 57 or lipids. 45 3) γδ T cells are directly and powerfully stimulated by phosphorylated microbial metabolites or phosphoantigens. 58 Among these, the most potent activator capable of stimulating Vδ2+ is HMBPP [E-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate], a sub-product of the synthesis of isoprenoid by the non-mevalonate pathway synthesised by bacteria and protozoa. 59 They are also activated at much higher concentrations by isopentenyl pyrophosphate, a derivative produced by eukaryotic cells via the mevalonate metabolic pathway. 43, 58 Aminobisphosphonates such as alendronate, pamidronate, or zoledronate [currently used in clinical practice for the treatment and prevention of osteoporosis] have been employed for the in vivo and in vitro activation of these lymphocytes, since they increase the intracellular concentration of secondary phosphoantigens by inhibiting the enzyme of the mevalonate pathway farnesyldiphosphate synthase. 48, 58 Synthetic phosphoantigen derivatives, such as bromohydrin pyrophosphate [Phosphostim®] , have been successfully used to stimulate γδ T cells ex vivo in clinical trials. 49 These specific characteristics of γδ T cells and their great plasticity enable a swift response against a wide range of antigens, making γδ T cells a key element in the defence against infections and tumours, and in the regulation of the immune response in many chronic and autoimmune inflammatory diseases. 16, 17, 43 61 The γδ T cells have been shown to be capable of opsonising and engulfing infected cells directly. 62 2) Secretion of proinflammatory cytokines, above all Th1 type [such as IFN-γ or TNF-α], which are essential for controlling intracellular microbes. 63 3) Activation of the immune response locally, thereby promoting the maturation of dendritic cells 64 and the anti-infection response of macrophages and NK cells. 
The role of γδ T cells in defence against infections
The alterations in innate immunity in CD and the loss of integrity of the intestinal barrier can lead to recurrent exposure to microbes that perpetuate intestinal inflammation. [4] [5] [6] [7] [8] [9] [10] In this regard, there is strong evidence for the fundamental role of γδ T cells in the immune response against pathogens [excellent reviews in refs 16 and 68 ]. γδ T cells display antiviral effects in several acute and chronic viral infections and against common parasites, and are also capable of triggering a rapid immune response in a number of bacterial infections, including salmonellosis, brucellosis, legionellosis, tularaemia, listeria, tuberculosis, and infections by Escherichia coli.
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The Role of γδ T Cells in Intestinal Inflammation
Role of γδ T cells in intestinal inflammation: preclinical studies
There is a large body of evidence for the protective role of γδ T cells in intestinal inflammation in several murine models. [18] [19] [20] [21] [22] [23] [24] [25] This is consistent with their role in mucosal infections, tissue repair, and regulation of the immune response. [61] [62] [63] [64] [65] [66] The anti-inflammatory effects of γδ T cells have been demonstrated in animal models resembling ulcerative colitis [ 20, 22 A later study confirmed their role in protection against colitis in two murine models of UC [DSS and IL-2 k.o. mice]. 24 The authors showed that γδ T cells are also capable of controlling the production of IFN-γ, probably secreted by αβ T cells. 24 Other studies used colitis induced by intrarectal 2,4,6-trinitrobenzene sulphonic acid [TNBS]─a model resembling CD─to show that the passive transfer of αβ T cells [and not γδ T cells] was capable of inducing colitis 18 ; and that depletion of γδ T cells with monoclonal antibodies [and not αβ T cells or T-helper cells] increased the severity of colitis and even mortality. 19 This aggravation of the lesions with increased mortality following γδ T depletion was corroborated in later work. 21 Kühl et al. used TNF ΔARE/+ mice that present a transmural ileitis similar to CD with extraintestinal manifestations [arthritis] , showing that γδ T cells depletion caused a histological aggravation and lower levels of TGF-β. 21, 24 Two key studies by Inagaki-Ohara et al. and Hoffmann et al. opened up the possibility of using γδ T cells as immunological therapy in IBD, after showing that their selective transfer decreased inflammation and even mortality in two different TNBS mice models [Cδ-/-and IL-10 transgenic]. This occurred through diminished production of TNF-α and increase in IL-10 and TGF-β. 23, 25 Nevertheless, although several preclinical studies have revealed the importance of γδ T cells as agents protecting against inflammation, there is no common agreement on their pro-or anti-inflammatory role, as inflammation-inducing effects have also been reported in some transgenic murine models of colitis. [26] [27] [28] [29] The main preclinical studies of γδ T cells in animal models of intestinal inflammation are shown in Table 1 .
Role of γδ T cells in Crohn's disease: studies in humans
Several groups have conducted studies on γδ T cells in the PB and intestinal mucosa of patients with CD in an attempt to explain their role in situ in humans [ Table 2 ].
Peripheral blood γδ T cells in Crohn's disease
The majority of studies of lymphocytes in the PB of patients with CD show the presence of lymphopenia, with heterogeneous results regarding circulating γδ T cells. [33] [34] [35] [36] [37] [38] [39] [40] Several previous studies have analysed PB for γδ T cells in CD. In a small sample of nine patients, Giacomelli et al. observed a significant increase in γδ T cells in PB in active CD only, especially by expansion of the subtype Vδ1+. 33 Bucht et al. also found higher values of γδ T cells [with a relative increase in the subtype Vδ1+] in eight patients with CD with respect to controls, 34 a finding that was confirmed in a later study carried out by the same group. 35 We recently published a study comparing the PB levels of different lymphocyte sub-populations in 40 patients with CD and 40 controls. Patients with CD had lymphopenia and a pronounced deficit of γδ T cells affecting all the subtypes studied [CD4+γδ T cells, CD8+γδ T cells, and CD56+γδ T cells], in particular the CD8+ γδ T cell subset, where it was independent of disease activity [remission or active disease] and of the treatments used. 38 These data suggest a possible immune disorder in CD affecting this sub-population and contributing to recurrent inflammation, thus corroborating the data obtained in experimental studies in mice. [18] [19] [20] [21] [22] [23] [24] [25] This deficit of γδ T cells in PB has recently been confirmed in a later study involving a larger sample of 102 patients with CD and controls. 69 A recent study showed similar results, with significantly lower numbers of Vδ2+ T cells in 12 paediatric patients with moderate CD without any immunosuppressant treatment, compared with controls with irritable bowel syndrome. 40 A selective PB depletion of the subtype CD27+ [related to Th1 response and TNF-α] was also observed, with a simultaneous increase in colonic biopsies. 40 In addition, the same study showed a selective ablation of Vδ2+ cells in the PB of azathioprine-treated patients. • Immunoregulation and protection of the mucosa in infections [14] [15] [16] 55, 60, 61, 64, 67 • 
G r a n z y m e s / P e r f o r i n G r a n z y m e s / P e r f o r i n It is striking that none of the studies published reported an increase in the total number of γδ T cells [or of the subtype Vδ2+] in PB in patients with active CD. It is known that this population increases significantly following infections, with values that can reach up to 30-40% of the total T cells. 53 Hence, a secondary expansion could be expected in the active phases of the disease [in which there is an increase in permeability and recurrent micro-infections]. This lack of expansion of the γδ T cells in active CD is consistent with the deficiency observed in these studies, and would support the notion of an altered immune response of the γδ T cells in CD. 38, 40, 41 An alternative explanation for this apparent lack of expansion could be a rapid recruitment of γδ T cells to the mucosa. Further studies comparing the different subtypes in PB and in the intestine, in different CD phenotypes and clinical scenarios, are warranted to clarify the meaning of this deficiency. Interestingly, our own preliminary data suggest an inverse relationship between the numbers of γδ T cells in PB and the clinical and endoscopic disease activity. 
IN Fγ
γδ T cells in the intestinal mucosa in Crohn's Disease
Studies on γδ T cells in the intestinal mucosa in CD have shown contradictory results. Three studies have showed a decrease of γδ T cells in the intestinal mucosa of patients with CD. 31, 34, 36 Fukushima et al. were the first to observe a significant decrease of γδ T cells in the mucosa in CD. The IEL γδ/CD3 T cell ratio was 13% in CD vs 36% in controls, and that of the lamina propria lymphocytes [LPL] was 4% in CD vs 15% in controls. Most of the LPL were CD4-CD8-. 31 Another study also showed a decrease in γδ T cells [sub-population Vδ1+] in inflamed compared with non-inflamed mucosa in four CD patients. The authors interpreted these findings as possibly being due to the destruction of the epithelial barrier or to a local expansion of αβ T cells in the inflamed mucosa. 34 Lee et al. reported a significant decrease in the sub-populations CD3+, αβ TCR+, and γδ TCR+ in the intestinal mucosa of patients with CD, with respect to controls. A significant decrease in γδ T cells was also observed in patients with CD compared with patients with UC, which would suggest a different role of this sub-population in the two diseases. 36 Another study found no significant differences in the proportion of IEL or LPL γδ T cells in 14 patients with ileal CD, with respect to controls. 32 Conversely, other authors found an increase in Vδ1+ cells capable of producing IFN-γ and interacting with fibroblasts in inflamed areas, with respect to noninflamed areas in a broad series of surgical samples of CD, UC, and diverticulitis. Another recent study explored for the first time the molecules responsible for the intestinal migration of γδ T cells from PB of patients with CD and active UC. It was shown that the γδ T cells from both healthy subjects and patients with active IBD express the β7 chain of the α4β7 heterodimer, responsible for intestinal extravasation of lymphocytes, and that patients with IBD present an increased expression of CCR9 [chemokine receptor 9], a specific marker of migration to the small intestine. 39 These data agree with those of the studies carried out by McCarthy et al., showing that activated Vδ2+ cells display enhanced gut-homing potential and can populate the human intestinal mucosa. 39, 63 Moreover, Kadivar et al. recently showed that a new subset of γδ T cells expressing CD8αβ+ are reduced in the gut of patients with active IBD, correlate negatively with disease activity, and normalise after anti-TNF [adalimumab] therapy, suggesting a 'protective' role for this subset in IBD. 41 
Gammadelta T Cells in Clinical Therapy
γδ T cells have been used in several clinical trials, especially as antitumour immunotherapy [reviewed in refs 47 and 48 ]. These cells possess a powerful cytotoxic capacity independent of MHC, which enables them to act against haematopoietic and solid tumours. 47 Ligands expressed in tumour cells can be recognised by γδ T cells, activating their anti-tumour action by secretion of IFN-γ and TNF-α, and cytotoxins such as granzyme B or perforins. 47, 48, 54, 56, 65 Moreover, a recent study across 39 different human malignancies showed that intra-tumoral γδ T-cell signatures emerged as the most significant favourable cancer-wide prognostic factor. 70 Two strategies have been tried to use γδ T cells as anti- The anti-tumour action of ex vivo activated autologous Vδ2+ [Vγ9Vδ2] transfer has been shown to be well tolerated and effective, especially in advanced tumours such as renal cancer. 49 Expansion of Vδ2+ [Vγ9Vδ2] in vivo has also shown promising results. The use of zoledronate and low doses of IL-2 in patients with advanced breast and prostate cancer was well tolerated, and produced a sustained activation and maturation of γδ T cells, which also correlated with a positive clinical response. 49 Currently, there are no clinical studies describing the use of these cells as immunotherapy in intestinal inflammatory diseases in humans, such as IBD.
The Role of γδ T Cells in CD: Friend or Foe?
The singular characteristics of γδ T cells, their great plasticity, and their possible use in immunotherapy, have stimulated their study in the pathogenesis of CD. Yet, their role in CD remains unclear and the γδ T cells may act both to protect against, and to induce, inflammation.
There is some evidence for a protective effect of γδ T cells in intestinal inflammation in line with their role against infections, in regeneration of the mucosa, and as regulators of immunity in humans, 41, [61] [62] [63] [64] [65] [66] corroborating preclinical data. 19, [23] [24] [25] Other studies in humans, however, point to their possible pro-inflammatory role in CD, especially the Vδ2+ subtype with a committed gut-trophic profile. 39, 40, 63 Apparently contradictory phenomena, such as the capacity of human γδ T cells [Vδ2+] to contribute to intestinal inflammation by enhancing IFN-γ production by αβ T cells, 63 and to have regulatory characteristics inhibiting αβ T cell proliferation [CD4+] and producing anti-inflammatory cytokines like TGF-β, 66 need to be investigated further in order to understand the plasticity of these cells in the different contexts of infection or inflammation. Some data suggest that there may be a primary deficiency of this cell type in patients with CD, in line with other previously reported defects in the innate immune defence mechanisms in this disease. 4, 5, [8] [9] [10] In fact, several studies have reported lower values of γδ T cells in the PB of patients, 38, 40 independently of clinical activity and treatment. 38 The presence of low levels of IL-7 [one of their most powerful stimulants] in patients with CD, both in remission and with active disease, 71 would support the hypothesis that this γδ T deficiency is characteristic of the disease and could have clinical consequences, favouring an altered response against microbes that can perpetuate the intestinal inflammation. Remarkably, other positive regulatory mediators of γδ T cells like TNF-α are, on the contrary, increased in CD, suggesting a more complex regulation. 72 In this regard, a recent report suggests that CD patients are a group at risk for opportunistic infection by an intracellular microorganism of the fungus family, Microsporidia. This microorganism may take advantage of defects in cell immunity and, specifically, of the γδ T cells. 73 Our case-control study including 36 CD patients and 36 healthy individuals also showed an inverse correlation between IgE anti-Encephalitozoon [a subspecies of Microsporidia] antibodies and γδ T cell numbers, especially CD8+ γδ T cells. 73 Recent data, showing that a new subset of γδ T cells expressing CD8αβ+ are lower in the gut of active IBD patients, correlate negatively with disease activity and normalise after anti-TNF [adalimumab] therapy, suggests also a 'protective' role in CD. 41 In contrast, other authors noted an increase in γδ T cells in PB of patients with CD, especially during active disease, and of the subtype Vδ1+. 30, [33] [34] [35] In line with this, McCarthy et al. provided evidence for a selective depletion of Vδ2+ T cells expressing CD27 [with high expression of intestinal migration β7 integrins and a T1 response with high production of TNF-α], which was simultaneously increased in colon biopsies. 40 Thus they propose that, despite having a γδ T-cell deficiency in PB [at least in paediatric CD patients], some cells with a high degree of activation [capable of producing TNF-α and IL-17A, and stimulating the production of IFN-γ by αβ T cells] manage to migrate to inflamed areas in the intestine. 40, 63 Although no clear data are available about the clinical consequences of these alterations of γδ T cells in PB, a recent study from our group on patients with CD revealed an inverse correlation between the serum values of γδ T cells [and not αβ T cells] and clinical and endoscopic activity. 69 One possible explanation for this selective effect of the γδ population is that their numbers were relatively much lower than their αβ counterparts in the PB of CD patients compared with controls in our cohort [67% relative decrease in γδ T cells vs 21% decrease in αβ T cells in CD vs controls], suggesting an specific alteration in this sub-population. 38 This is in line with preclinical studies showing that the selective depletion of γδ T cells [and not their αβ counterparts] aggravated inflammation and increased mortality in mice. 19 Other factors affecting primarily the γδ subpopulation in active patients [like a specific drug used in that setting depleting them selectively] need further investigation. These findings reinforce the relation between γδ T cell deficiency and the more severe forms of the disease, and a possible role for γδ T cells as a predictive biomarker.
There is currently no general agreement about the location and the role of γδ T cells in the intestinal mucosa in CD, which makes it more difficult to interpret their role on a local level. Some authors detected a decrease in the γδ T cell population in biopsies from CD patients compared with controls, especially in the ileum. 31, 36 Others, however, found no significant differences in the percentage of γδ+ IEL or LPL, 32 or even observed an increase of these cells in colon biopsies, although without reaching statistical significance. 30 One study showed a decrease in γδ T cells in inflamed vs non-inflamed mucosa, although in a limited number of patients. 34 These contradictory results from studies on γδ T cell distribution are not exclusive to CD, since similar phenomena have been reported in other chronic inflammatory diseases. 17 Likewise, it has been shown that γδ T cells can have both anti-tumour activity and favour tumour growth, in different immunological contexts, showing their plasticity. 48 Another possible explanation for these discrepancies is the possibility that the different subtypes of γδ T cells may have distinct actions and effects in CD since, like their αβ counterparts, they can secrete a wide range of both pro-and anti-inflammatory cytokines. 60, 63, 66 Vδ2+ are predominant in PB; they are powerfully stimulated directly by phosphorylated microbial metabolites and have a greater cytotoxic capacity, which has made them suitable for immunotherapy. [47] [48] [49] 55, 56 In CD patients, activated Vδ2+ displaying enhanced guthoming potential [with higher expression of CCR9] and a higher production of pro-inflammatory cytokines [TNF-α and IL-17A] can populate the human intestinal mucosa. Azathioprine selectively and reversibly ablates this population, suggesting an active role of this subtype in the disease pathogenesis and a possible therapeutic role of targeting specifically Vδ2+ T cell responses in addition to conventional lymphocyte responses, or blocking selectively their migration to the intestine from the PB. 39, 40 Vδ1+ are predominant in the intestinal epithelia, present specific characteristics of motility and migration, and are key players in epithelial regeneration. [12] [13] [14] [15] A relative increase in Vδ1+ has been demonstrated in the PB of patients with CD. 34, 35 Remarkably, large numbers of activated Vδ1+ γδ T cells are present in the lymphoid aggregates of patients with UC, with a direct relationship between their number and the severity of the inflammation. 74 It thus appears that the Vδ1+ subtype may play an important role in chronic inflammation in the epithelia, since similar findings have been reported in other conditions like coeliac disease. 50 However, a distinct type of Vδ1+ T cells expressing CD8αβ+ are decreased in the gut of active CD patients and correlate negatively with disease activity, suggesting a regulatory ['anti-inflammatory'] role, thus showing the complexity of the different γδ T cells subsets in IBD. 41 This regulatory potential of γδ T cells could be used in immunotherapy against intestinal inflammation in CD. In fact, preliminary data on regulatory T cell therapy development for CD have recently been published. 75 The third main subtype Vδ3+ has recently been identified in healthy human intestinal mucosa. 50 They have been shown to release a wide range of cytokines and promote the maturation of dendritic cells, 51 but their role in IBD is currently unknown. It is also possible that exposure of the different subtypes of γδ T cells in different cytokine micro-environments in inflamed tissues could activate distinct genes, with opposing effects. If this is the case, the diverse interactions of γδ T cells with the microbiota, epithelial cells, and other immune cells [such as macrophages] would result in different immune responses. Further investigation on these interactions in different clinical settings may lead to new therapeutic approaches using γδ T cells as targets for immunotherapy in IBD.
Conclusions and Future Directions
Crohn's disease is a chronic recurrent systemic disease affecting any part of the gastrointestinal tract, typically the ileocaecal area. An altered immune response to commensal intestinal bacteria takes place in genetically predisposed individuals, resulting in chronic inflammation. Several alterations in the innate immunity mechanisms have been reported in recent years, leading to the presence of micro-infections that are not efficiently resolved by the immune system, leading to chronic inflammation.
γδ T cells constitute only a small proportion of the lymphocytes that circulate in the blood and peripheral organs and are present mainly in the epithelia, where they can account for up to 40% of IEL of the intestinal mucosa. Their lack of MHC restriction and their singular plasticity and immunoregulatory properties make them key cells in the first line of defence against infections and in wound healing. These unique features, their known participation in the pathogenesis of other autoinflammatory conditions, and the results from animal and human studies published to date, point to an important role of γδ T cells in the pathogenesis of CD. However, their clinical relevance in IBD is still not fully understood. Some animal studies indicate that they may play a protective role against colitis, whereas others have shown a possible deleterious role. In humans, there is evidence that patients with CD present a γδ T-cell deficiency in PB, with possible clinical consequences. Other studies, however, have identified pro-inflammatory phenotypes that could contribute to intestinal inflammation.
These contradictory effects must be studied in depth in order to know the biology of this type of lymphocyte, its interaction with the microbiota and the epithelial cells, and its relation with other innate and acquired immunity cells. A systematic study of the different subpopulations of γδ T cells [Vδ1+, Vδ2+, Vδ3+], as well as their different phenotypes, within the different clinical contexts of a heterogeneous disease like CD will allow some of these key issues to be solved.
The study of the relations between γδ T cells in PB and in the mucosa [both inflamed and non-inflamed], together with the migration mechanisms, their possible prognostic value, their correlation with opportunistic infections, the effect of treatments, and their role in the different phenotypic forms of CD [including the extraintestinal manifestations] will help to define better their true importance in the pathogenesis and clinical symptoms.
Furthermore, one may speculate on the possibility of using immunoregulatory treatments involving γδ T cells to modulate their action and improve the propensity to down-regulate the inflammatory responses by optimising the immune response in the intestinal mucosa in CD. In fact, clinical trials have already been conducted, showing that manipulation of these cells in immunotherapy against cancer is effective and well tolerated, possibly leading the way for a new possible therapeutic alternative in the future for CD patients.
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